



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) **EP 0 959 134 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
24.11.1999 Bulletin 1999/47

(21) Application number: 97941191.5

(22) Date of filing: 18.09.1997

(51) Int. Cl.⁶: **C12N 15/85**, **C12N 9/12**,
C12N 1/19
// (**C12N9/12**, **C12R1:865**),
(**C12N1/19**, **C12R1:865**)

(86) International application number:
PCT/JP97/03305

(87) International publication number:
WO 98/12336 (26.03.1998 Gazette 1998/12)

(84) Designated Contracting States:
FR GB

(30) Priority: 18.09.1996 JP 24674996

(71) Applicant: Dnavec Research Inc.
Ibaraki 305 (JP)

(72) Inventors:
• **ISHIKAWA, Fuyuki**
Kouhoku-ku Yokohama-shi Kanagawa 222 (JP)

• **HASEGAWA, Mamoru**
Tsukuba-shi Ibaraki 305 (JP)

(74) Representative:
Straus, Alexander, Dr. et al
Patentanwälte
Becker, Kurig, Straus
Bavariastrasse 7
80336 München (DE)

(54) ARTIFICIAL CHROMOSOME

(57) An artificial mammalian chromosome, more specifically, a clone containing a mammalian centromere sequence and a DNA replication origin with mammalian telomere sequences added to both ends of the clone, is provided by preparing a CEPH artificial yeast chromosome library containing a human genome, identifying clones having a repetitive human alphoid sequence from this library, and further preparing a yeast strain in which mammalian telomere sequences are added to the ends of its chromosome.

EP 0 959 134 A1

Description

Technical Field

[0001] The present invention relates to the field of genetic engineering, more specifically, it relates to an artificial mammalian chromosome prepared by genetic engineering techniques.

Background Art

[0002] Various methods of treating diseases attributed to an inherited or an acquired genetic defect, namely a genetic disease, have been developed. Gene therapy is one such method for treating a genetic disorder fundamentally by replacing a defective gene with a normal gene or complementing a normal gene.

[0003] At present, the most clinically and fundamentally developed method of introducing a gene comprises linking a short DNA fragment like cDNA to a downstream site of an ectopic enhancer or promoter that originally does not exist upstream of the gene, introducing the resulting DNA fragment into a cell using a virus or liposome, and allowing the cell to express the gene. This method is easy to manipulate because a short DNA fragment is used. Furthermore, it has a relatively high success rate of introducing a gene into a cell. However, there are some disadvantages. First, it is difficult to control the expression of an introduced gene. In this method, the expression control of a desired gene in a human *in vivo* is difficult because the promoter and enhancer used are derived from viruses. Second, the existing pattern of an introduced gene in a cell is not stable. Untargeted genes may be destroyed or an excessive number of introduced genes may exist. This is because the introduced gene in a cell may be randomly integrated into a chromosomal DNA. Alternatively, the introduced gene may independently exist extrachromosomally and be maintained without being controlled by DNA synthesis during the S phase or chromosome separation during the M phase of a cell. This fact makes it difficult to control expression of a therapeutic gene in gene therapy and to exhibit therapeutic effects continuously.

[0004] For example, sickle cell anemia and thalassemia drew the most attention in the early 1980s as targets for gene therapy. In spite of numerous patients with these diseases, it is not being studied much at present because it is difficult to strictly control the expression of the therapeutic gene (a globin gene) to be introduced. Furthermore, since processing of a huge DNA molecule like a globin gene using restriction enzymes is limited, homologous recombination using yeast is more effective than recombination using an *E. coli* plasmid. A stable chromosome can thus be prepared in a yeast cell. If such a chromosome is capable of replicating in a human cell, it can be used for the most ideal gene therapy. In the field of gene therapy, it is

essential to develop a vector system in which a human gene with an expression control region can function and be stably maintained in a human cell.

[0005] An "artificial chromosome" that is a yeast artificial chromosome (YAC) vector has been developed. A long-chain DNA molecule such as a gene ligated to a promoter region and/or an enhancer region can be introduced into this vector and stably maintained following the mechanisms of DNA replication and separation in yeast. A DNA fragment requires three functional structures, a centromere, a DNA replication origin, and a telomere, to function as a chromosome. Based on this fact, the YAC vector has been constructed to contain genes for these three functional structures.

[0006] However, the above yeast functional structures do not function in mammals, including humans. Therefore, the functional structures from a mammal or those modified to a mammalian type structure must be used to constitute an artificial chromosome that functions in a mammalian cell.

[0007] A centromere, a DNA replication origin, and a telomere of yeast each consist of a several kb DNA sequence whose functions have been well analyzed. In contrast, a centromere of a mammal, especially of a human, is a huge DNA molecule in which a repetitive sequence called the alphoid sequence repeats over several hundred kb or more. In addition, even the primary structure of a mammalian DNA replication origin has not been clarified. Thus, the analysis of functional structures in a mammal is far behind that in yeast, and an artificial mammalian chromosome has yet to be constructed.

[0008] Mammals, including humans, commonly have a 5'-TTAGGG-3' sequence as a repetitive unit of a telomere sequence.

Disclosure of the Invention

[0009] An objective of the invention is to provide an artificial mammalian type chromosome, more specifically, an artificial chromosome having a mammalian type telomere sequence added to both its ends. The current invention provides a yeast strain capable of having a mammalian type telomere sequence connected to both ends of its chromosome.

[0010] A chromosome requires minimum functional structures of three elements to function. The first is a DNA replication origin region that ensures a single DNA replication during the S phase following mitosis. The second is a centromere that ensures the correct separation of each set of replicated DNA into daughter cells. The third is a telomere that caps the ends of linear chromosomes to ensure their stable existence in a nucleus.

[0011] It is evident that a centromere sequence of a mammal, especially of a human, is a huge DNA molecule containing a specific DNA sequence called the repetitive alphoid sequence that repeats over a few hundred kilo base pairs in tandem (M. Ikeno, H. Masumoto

& T. Okazaki, Hum Mol Genet 3: 1245-1257 (1994)). Such a huge DNA molecule cannot be manipulated by means of conventional recombinant DNA techniques. Therefore, the present inventors employed a CEPH artificial yeast chromosome library containing a human genome inserted into a yeast YAC vector into which a long DNA molecule can be inserted. Clones containing the repetitive human alphoid sequence were identified from this library to serve as the basis of an artificial mammalian chromosome. The primary structure of a DNA replication origin in a human genome has not been identified, however, it is estimated that one DNA replication origin exists on average in each 100 kb of a human genome DNA (Molecular biology of cell, third edition, Kyoikusha). Therefore, a YAC clone containing the above-described repetitive alphoid sequence is thought to contain a DNA replication origin.

[0012] However, the YAC clone itself does not function as an artificial mammalian chromosome due to the lack of a telomere sequence. Thus, the present inventors engaged in searching for a method of adding a mammalian telomere sequence to the ends of DNA of the thus-obtained YAC clone.

[0013] Specifically, the present inventors engaged in investigating a method for adding a telomere sequence not *in vitro* but *in vivo* (in yeast), in other words, a method for preparing a yeast strain in which a mammalian telomere sequence can be added to a yeast genome, considering that a desired artificial chromosome is a long-chain DNA molecule and is easily damaged and physically decomposed by nonspecific enzymes.

[0014] A telomerase consists of a protein component and an RNA component as a template for extending the telomere sequence. The telomere sequence is added to a chromosome as a complementary sequence to the template RNA. The present inventors modified a template RNA encoding a yeast telomere sequence (TG₁₋₃)_n so as to encode a mammalian telomere sequence (TTAGGG)_n by *in vitro* mutagenesis, cloned the modified template RNA in an expression plasmid, then introduced the plasmid into yeast. A hybrid telomerase (composed of a mammalian template RNA derived from the plasmid and protein derived from host yeast) was constructed in yeast. Thus, a yeast strain that replaces the yeast chromosomal telomere sequence with a mammalian telomere sequence was prepared. The mammalian telomere sequence was confirmed to be added to the yeast chromosome in the strain.

[0015] In summary, the present invention relates to:

- (1) An artificial chromosome having a mammalian telomere sequence added to its ends.
- (2) The artificial chromosome of (1), wherein said chromosome comprises an alphoid sequence.
- (3) The artificial chromosome of (1) or (2), wherein said chromosome comprises a DNA replication origin and a centromere, both derived from an organ-

ism other than a mammal.

(4) The artificial chromosome of (3), wherein said organism other than a mammal is yeast.

(5) A hybrid telomerase capable of adding a mammalian telomere sequence to the ends of a chromosome, wherein said telomerase comprises a template RNA comprising a complementary sequence to a mammalian telomere sequence and a telomerase protein derived from an organism other than a mammal.

(6) The hybrid telomerase of (5), wherein said complementary sequence to a mammalian telomere sequence comprises 5'-CCCUAA-3'.

(7) The hybrid telomere of (5) or (6), wherein said organism other than a mammal is yeast.

(8) A method of producing a hybrid telomerase, which comprises producing a template RNA consisting of a complementary sequence to a mammalian telomere sequence in a host other than a mammal and allowing said template RNA to match with an endogenous telomerase protein of the host.

(9) The method of (8), wherein said host is yeast.

(10) The method of producing an artificial chromosome having a mammalian telomere sequence added to its ends, which comprises contacting any one of the hybrid telomerase of (5) to (7) to a chromosome.

(11) A eukaryotic cell capable of expressing a template RNA comprising a complementary sequence to a mammalian telomere sequence and capable of being the mammalian telomere sequence added to the ends of a chromosome in the cell.

(12) The eukaryotic cell of (11), wherein said cell is yeast.

(13) A method of producing an artificial chromosome having a mammalian telomere sequence added to its ends comprising introducing a chromosome into the cell of (11) or (12).

[0016] In the present invention, the term "chromosome" means a DNA molecule that exists stably as a single copy, independent of a host genome in the host, and is capable of replicating and separating following the host cell cycle. It generally contains a DNA replication origin, a centromere, and a telomere, and may be natural or artificial.

[0017] The artificial chromosome of the present invention means a chromosome containing at least a part not derived from the natural source.

[0018] The mammalian telomere sequence of the present invention means a sequence consisting primarily of repeated 5'-TTAGGG-3' sequences.

[0019] The method of constructing an artificial chromosome of the present invention is not particularly limited. For example, an artificial chromosome capable of functioning in mammalian cells can be constructed by inserting a DNA molecule containing a mammalian centromere sequence and a DNA replication origin into a

vector and adding a mammalian telomere sequence to the end of the vector.

[0020] The vector used in this method is not particularly limited as long as a long-chain DNA molecule can be inserted into it. An example of such a vector is the YAC vector.

[0021] The method of adding a mammalian telomere sequence is not particularly limited. The method of expressing a mammalian telomerase *in vivo* and allowing it the function is preferable because the DNA molecule suffers less physical damage and gene manipulation in cells is enabled using homologous recombination techniques. In this method, the mammalian telomerase includes a hybrid telomerase in which only the RNA template among the telomerase constituents is modified into a mammalian type. A telomerase can be modified into a mammalian type structure by modifying the TLC1 gene encoding an RNA template of a yeast telomerase (Singer, M.S., and Gottschling, D.E., Science, 266: 404-409 (1994)) by *in vitro* mutagenesis. This process replaces the DNA sequence "CAC-CACACCCACACAC" corresponding to the template region with the mammalian type DNA sequence "CACCTAACCCCTAACCC," expressing the mutant TLC1 gene in yeast. The resulting expression product is then allowed to associate with a yeast telomerase protein *in vivo*, thereby reconstituting a functional hybrid telomerase.

[0022] A desired gene that should function in the cell can be inserted into the artificial chromosome constructed by the above method and then introduced into a target cell. Any type of gene can be used. Since, theoretically, a DNA molecule of any length can be inserted into the artificial chromosome of the present invention, it is possible to use cDNA or a gene containing an expression regulatory region, such as a promoter or an enhancer, at the *cis* position located on the upstream side of the gene. Multiple genes can be used together. The artificial chromosome of the present invention can be applied to gene therapy in which expression of the gene must be strictly controlled, for example, gene therapy of a hemoglobin gene in thalassemia. More specifically, the artificial chromosome can be used to introduce a lengthy DNA molecule including a *cis* region necessary to control expression or to treat diseases caused by the lack of a long DNA region, such as chromosomal aberration, by supplementing a whole DNA region.

[0023] The artificial chromosome of the present invention can be introduced by microinjection or lipofection into an animal cell. Specifically, cell fusion is preferable because the artificial chromosome suffers less physical damage.

[0024] Any cell into which the artificial chromosome is to be introduced can be used as long as the artificial chromosome can function in the cell. For example, a mammalian cell from a primate other than a human can be used if an artificial chromosome has a mammalian telomere sequence at its ends and a mammalian

aliphoid sequence. A rodent such as a mouse may also be used.

Best Mode for Implementing the Invention

Example 1 Preparing YAC clones containing a human centromere sequence and a human DNA replication origin

[0025] Clones containing a human aliphoid sequence were selected from a CEPH artificial yeast chromosome library which was constructed by inserting a human genome into a YAC vector capable of incorporating a long-chain DNA molecule according to the method described in Hum. Mol. Genet. 3: 1245-1257 (1994).

[0026] As a result, five clones, 749H1, 818H1, 858F11, 882C10, and 831B6, possessed a human chromosome XXI aliphoid sequence in the CEPH YAC library. Among these five clones, 858F11, which was 800kb long and carried approximately 55 kb of the aliphoid sequence (presumably including a human DNA replication origin), was used in the following experiment.

[0027] Since the pYAC4 vector used in the CEPH YAC library does not have markers for a mammalian cell, 858F11 clone-carrying yeast cells were transformed with a *Sall/ClaI* fragment of pYACNeoNot (provided by Howard Cooke, Medical Research Council (MRC) Human Genetics Unit, Edinburgh, UK). Neomycin-resistant gene *neo* and the SUP4 gene were then introduced into the 858F11 clone by homologous recombination. Southern hybridization was performed to confirm that an aliphoid sequence was maintained in the YAC clone.

Example 2 Preparing a yeast strain to add a mammalian type telomere sequence

(1) Humanizing a template RNA of yeast telomerase

[0028] *S. cerevisiae* reportedly has a TLC1 gene encoding a template RNA of telomerase. First, a mutation was introduced into a template region of the TLC1 gene by *in vitro* mutagenesis to prepare a mutant TLC1 allele (hereinafter referred to as HTM3) which codes a human telomere sequence (TTAGGG)_n in stead of a yeast telomere sequence (TG₁₋₃)_n. More specifically, a DNA sequence "CACACACCCACACAC," a template region of the TLC1 gene encoding a template RNA of a yeast telomerase, was converted to a human telomere sequence "CACCTAACCCCTAACCC." Moreover, the *PvuII/XhoI* cleavage site was introduced into the ends of the HTM3 gene using Tag primer.

(2) Over-expression of HTM3 using a GAL promoter

[0029] A *PvuII/XhoI* fragment of HTM3 was inserted into the *PvuII/XhoI* site of pYES2 vector (hereinafter referred to as YEpUGH3). The pYES2 vector is an

expression vector having a URA3 gene, a 2 μ m plasmid replication origin, and a GAL1 promoter. Yeast cells were transformed with YEUG3, and HTM3 was over-expressed in the transformants using a GAL1 promoter to obtain a mutant yeast strain (hereinafter referred to as Yeast Human Telomere Marker (YHTM)) having a functionally modified telomerase which synthesizes the human telomere sequence *in vivo*.

[0030] Southern hybridization was performed to confirm that the functionally modified telomerase actually functioned in YHTM, in other words, that the human telomere sequence was added to the ends of the yeast chromosome. Southern hybridization was conducted using oligo DNA (CCCTAA)₄ corresponding to the human telomere sequence as a probe in a hybridization solution containing 5xSSPE, 0.5% SDS, 0.5x Denhardt, and 20 μ g/ml of h.s. DNA at 42 °C. After the reaction, the filter was washed twice using a solution containing 1xSSRE and 0.1% SDS at room temperature for 10 minutes then washed again using a solution containing 0.1xSSPE and 0.1% SDS at room temperature for 10 minutes. After the washing, the obtained band was detected using a FUJI Image Analyzer and exposure for 20 hours. As a result, a band was detected at an expected position, confirming that the human telomere sequence was added to the yeast chromosome.

[0031] The ends of the yeast chromosome were then cloned, and the base sequences were determined. First, a yeast genome DNA was extracted, blunted by using T4 polymerase, then cleaved by restriction enzyme *Xho*I. After agarose gel electrophoresis, 0.9 to 1.1 kbp fragments were obtained from the gel. The fragment was then ligated with about a 2.9 kbp *Eco*RV/*Xho*I fragment derived from pBluscriptII SK (Toyobo), then the ligation product was used to transform *E. coli*. Colony hybridization was performed using a repetitive sequence of the yeast subtelomere region as a probe, positive clones were picked up, and the base sequences were determined using a standard method. As a result, about a 140 bp yeast telomere region was cloned. In this region, the human telomere sequence, CCCTAA, repeating two to five times, existed in tandem.

(3) Preparing a yeast strain in which TLC1 gene is replaced with HTM3

[0032] The TLC1 gene on the yeast chromosome was entirely replaced with HTM3 by homologous recombination in yeast to obtain a mutant yeast strain having in its genome a functionally modified telomerase gene that synthesizes a human telomere sequence. Cloning and determination of the sequence at the ends of YNH3 chromosome were conducted by using the method above. As a result, about a 190 bp yeast telomere region was cloned. In this region, a maximum of 18 repetitive telomere sequences of CCCTAA (109bp) existed in tandem towards the end.

Industrial Applicability

[0033] The present invention provides clones having a mammalian alphoid sequence and a yeast strain in which a mammalian telomere sequence can be added to the ends of the chromosome. The length of DNA to be introduced in the artificial chromosome of the present invention is theoretically unlimited. The artificial chromosome exists stably as a single copy, independent of a host genome in a host, and undergoes DNA replication and chromosome separation following the cell cycle of the host. For example, the artificial chromosome of the present invention can be constructed to contain a human therapeutic gene with an expression control region, and expression of the introduced gene can be regulated under the physiological conditions.

Claims

1. An artificial chromosome having a mammalian telomere sequence added to its ends.
2. The artificial chromosome of claim 1, wherein said chromosome comprises an alphoid sequence.
3. The artificial chromosome of claims 1 or 2, wherein said chromosome comprises a DNA replication origin and a centromere, both derived from an organism other than a mammal.
4. The artificial chromosome of claim 3, wherein said organism other than a mammal is yeast.
5. A hybrid telomerase capable of adding a mammalian telomere sequence to the ends of a chromosome, wherein said telomerase comprises a template RNA comprising a complementary sequence to the mammalian telomere sequence and a telomerase protein derived from an organism other than a mammal.
6. The hybrid telomerase of claim 5, wherein said complementary sequence to the mammalian telomere sequence comprises 5'-CCCUGA-3'.
7. The hybrid telomere of claim 5 or 6, wherein said organism other than a mammal is yeast.
8. A method of producing a hybrid telomerase, which comprises producing a template RNA comprising a complementary sequence to a mammalian telomere sequence in a host other than a mammal and allowing said template RNA to match with an endogenous telomerase protein of a host.
9. The method of claim 8, wherein said host is yeast.
10. A method of producing an artificial chromosome

having a mammalian telomere sequence added to its ends, which comprises contacting any one of the hybrid telomerase of claims 5 to 7 with the chromosome.

- 5
11. A eukaryotic cell capable of expressing a template RNA comprising a complementary sequence to a mammalian telomere sequence and capable of having the mammalian telomere sequence added to the ends of its chromosome in the cell. 10
12. The eukaryotic cell of claim 11, wherein said cell is yeast.
13. A method of producing an artificial chromosome 15
having a mammalian telomere sequence added to its ends comprising introducing the chromosome into the cell of claim 11 or 12.

20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/03305

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl ⁶ C12N15/85, C12N9/12, C12N1/19 // (C12N9/12, C12R1:865) (C12N1/19, C12R1:865) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl ⁶ C12N15/85, C12N9/12, C12N1/19 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPI (DIALOG), BIOSIS (DIALOG)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y A	Hum. Mol. Genet. 3(8) (1994) S.S. Taylor "Addition of functional human telomeres to YACs" p. 1383-1386	1 - 4 5 - 10 11 - 13
Y A	Genes & Development 8(5) (1994) C. Autexier "Functional reconstitution of wild-type and mutant Tetrahymean telomerase" p. 563-575	5 - 10 1-4, 11-13
Y A	Proc. Natl. Acad. Sci. USA 85 (1988) R.K. Moyzis "A highly conserved repetitive DNA sequence, (TTAGGG) _n , present at the telomeres of human chromosomes" p. 6622-6626	6, 7 1-5, 8-13
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search December 11, 1997 (11. 12. 97)		Date of mailing of the international search report December 24, 1997 (24. 12. 97)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)